- PHASE IIb RESULTS OF LATANOPROSTENE BUNOD FOR REDUCTION OF IOP PRESENTED. Robert N. Weinreb, MD, presented the Phase IIb results for latanoprostene bunod (previously known as BOL-303259-X) at the American Glaucoma Society 23rd Annual Meeting on March 2. Dr. Weinreb is chairman and distinguished professor of Ophthalmology, University of California San Diego and director, Shiley Eye Center and Hamilton Glaucoma Center. Latanoprostene bunod, a nitric oxide-donating prostaglandin F2 alpha analog, licensed by Nicox to Bausch + Lomb, is being developed for the reduction of IOP in patients with glaucoma or ocular hypertension. This dose-ranging study showed that latanoprostene bunod is effective at lowing IOP at multiple concentrations in a dose-dependent manner and that latanoprostene bunod 0.024% q.d. statistically significantly reduced IOP greater than latanoprost with a similar side effect profile. The randomized, investigator-masked study enrolled 413 patients across 23 sites in the United States and Europe. In light of the positive results of this study, Bausch + Lomb initiated a Phase III clinical program of latanoprostene bunod in January 2013 that includes two separate, randomized, multicenter, double-masked, parallel-group clinical studies, APOLLO and LUNAR, designed to compare the efficacy and safety of lantoprostene bunod administered q.d. with timolol maleate 0.5% administered b.i.d. in lowering IOP in patients with open-angle glaucoma or ocular hypertension. Read more
- CENTERVUE INTRODUCES HANDHELD BINOCULAR REFRACTOMETER. CenterVue recently introduced the 2WIN For Vision, a handheld binocular refractometer. In five seconds, at one-meter distance, the 2WIN accurately measures refraction in the most natural vision conditions. It is also a vision analyzer, as it provides an objective assessment of the visual function, including pupil distance, pupil size, gaze and check of lens correction in use. The 2WIN is handheld, lightweight and easy-to-use. The company is also launching a new proprietary telemedicine platform, the Eye Knowledge Network (EKN). The EKN is a fully tested cloud system that transmits retinal images over the Internet and makes them available for online consultation by authorized users. It ensures fully encrypted, HIPPA-compliant data transmission and works seamlessly with CenterVue's automated fundus camera, the DRS. Visit the company's
website for additional information.
- PROGRESSIVE CHOICE FREEFORM LENS SERIES LAUNCHED BY ZEISS. Carl Zeiss Vision has launched a new customized progressive lens series designed for the competitive market environment that eye-care professionals face today. The Choice series consists of three new progressive lenses: ZEISS Progressive Choice, ZEISS Progressive Choice Plus and ZEISS Progressive Choice Plus V. ZEISS Progressive Choice lenses are optically optimized for up to 30% larger fields of clear vision. Four corridor options, sized for 13 mm, 15 mm, 17 mm and 19 mm fitting heights, are available. No compensated powers are required for verification of the lenses. With ZEISS Progressive Individual 2, the Choice series creates a complete ZEISS customized lens portfolio with multiple levels of customization and price points, to meet more patients' vision and affordability needs. ZEISS Progressive Choice Plus offers the five corridor options for fitting heights of 13 mm, 15 mm, 17 mm, 19 mm and 21 mm. ZEISS Progressive Choice Plus V employs a corridor sized automatically in 0.1-mm increments to the fitting height of the patient's frame. Visit the company's
website for more information.
- WILLS EYE INSTITUTE'S JERRY SHIELDS, MD, TO RECEIVE NATIONWIDE HONOR. Wills Eye Institute recently announced that Dr. Jerry A. Shields, director of the Wills Eye Ocular Oncology Service, is to receive The National Physician of the Year Award in Clinical Excellence. The Awards recognize and honor five exemplary physicians, as well as the many thousands of other excellent physicians practicing in communities throughout the United States. For 40 years, Dr. Shields has diagnosed and treated countless patients with ocular tumors and has led clinical research to improve methods for the diagnosis and treatment of eye cancers, including tumors of the eyelids, conjunctiva, intraocular structures and orbit. He will receive the honor at a ceremony on Monday, March 18, 2013 at The Pierre Hotel in New York City.
- OWL TO HOST AWARDS RECEPTION AT ASCRS. Ophthalmic Women Leaders (OWL) will be hosting its annual awards reception honoring influential women in ophthalmology during the 2013 American Society of Cataract & Refractive Surgeons meeting in San Francisco. Three awards will be presented: Visionary Woman Award, sponsored by the Lindstrom Family Foundation; the Rising Star Award, sponsored by Link Consulting; and the Catalyst Award. Through March 15, OWL members will be able to nominate candidates for each of the three awards being presented. Nominations can be completed
here. The reception will be held at the W Hotel San Francisco (Industry Room, 2nd floor) on April 22 from 5:30 p.m. to 7:00 p.m. Admission is free for OWL members and $25 for non-members. Registration at
- CHRISTOPHER THATCHER NAMED DIVISION VICE PRESIDENT AND BUSINESS UNIT MANAGER AT REICHERT TECHNOLOGIES. Reichert Technologies, a unit of AMETEK Ultra Precision Technologies, recently named Christopher A. Thatcher as Division Vice President and Business Unit Manager. He will be based at the company's Buffalo, NY, headquarters and have responsibility for Reichert's global businesses.